Why ArriVent BioPharma (AVBP) is on investors’ radar

ArriVent BioPharma (AVBP) has drawn attention after recent trading, with the stock last closing at US$21.43 and showing mixed short term performance across the past week, month, and past 3 months.

At the current share price of US$21.43, ArriVent BioPharma’s recent 30 day share price return of a 7.99% decline contrasts with a 3.03% year to date share price gain and a 13.09% total shareholder return over the past year, suggesting momentum has cooled after earlier strength.

If you are comparing ArriVent BioPharma with other opportunities in a similar space, this could be a useful moment to scan for more healthcare focused AI names using the 34 healthcare AI stocks

With ArriVent still loss making but carrying a value score of 3 and trading at a large intrinsic discount, investors now face a key question: is this an underappreciated biotech story, or is the market already pricing in future growth?

Price to book of 3.1x, is it justified?

ArriVent BioPharma currently trades on a P/B of 3.1x, which screens as expensive relative to the broader US Biotechs industry but low against its direct peer set.

P/B compares a company’s market value with its net assets on the balance sheet. It can be a common reference point for early stage or loss making biotechs where earnings are still negative.

For ArriVent, the 3.1x P/B is higher than the 2.4x average for the US Biotechs industry. This suggests investors, at recent prices, are paying a premium compared to the wider group. However, that same 3.1x sits well below a peer average of 31.6x. This highlights a sharp gap between how the market is pricing ArriVent and how it is pricing similar names in the peer set.

Result: Price to book ratio of 3.1x (ABOUT RIGHT)

However, there are clear pressure points, including zero reported revenue, a US$166.308 million net loss, and the risk that key clinical programs or partnerships do not progress as expected.

Another view on valuation

The P/B of 3.1x paints ArriVent as expensive versus the US Biotechs average of 2.4x, but the SWS DCF model points the other way. The share price of US$21.43 is trading at an 88.2% discount to an estimated fair value of US$181.15. Which signal do you treat as more important?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ArriVent BioPharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 61 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of signals in the story so far, this is the kind of setup where you might want to move quickly and check the underlying data yourself rather than relying on headlines or short term moves alone. Then weigh up the 1 key reward and 3 important warning signs highlighted in the 1 key reward and 3 important warning signs

Looking for more investment ideas?

If ArriVent has caught your interest, do not stop here. Use the tools at hand to quickly scan other stocks that might fit your style and risk tolerance.

• Target potential mispriced opportunities by running your filters through the 61 high quality undervalued stocks.
• Prioritise balance sheet strength by focusing on companies in the solid balance sheet and fundamentals stocks screener (39 results).
• Hunt for underfollowed potential by checking the screener containing 26 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.